![]() |
Open for inclusion |
A phase 1/2 multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenaöodomide (Len) with or without dexametasone (Dex) in subjects newly diagnosed multiple myeloma (NDMM)Cancer type: Myeloma Phase: I/II Principal Investigator: Porkka Kimmo Country: FI Keywords: Finland, Helsinki Status: Open for inclusion |